CollPlant Biotechnologies (CollPlant Biotechnologies) Interest Coverage

: N/A (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. CollPlant Biotechnologies's Operating Income for the three months ended in Dec. 2023 was $-5.07 Mil. CollPlant Biotechnologies's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for CollPlant Biotechnologies's Interest Coverage or its related term are showing as below:

CLGN's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CollPlant Biotechnologies Interest Coverage Historical Data

The historical data trend for CollPlant Biotechnologies's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CollPlant Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

1.76

CollPlant Biotechnologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial															N/A	-	N/A	N/A	N/A

Competitive Comparison

For the Biotechnology subindustry, CollPlant Biotechnologies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CollPlant Biotechnologies Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Interest Coverage distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Interest Coverage falls into.

CollPlant Biotechnologies Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CollPlant Biotechnologies's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, CollPlant Biotechnologies's Interest Expense was $-0.01 Mil. Its Operating Income was $-7.51 Mil. And its Long-Term Debt & Capital Lease Obligation was $2.54 Mil.

CollPlant Biotechnologies did not have earnings to cover the interest expense.

CollPlant Biotechnologies's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, CollPlant Biotechnologies's Interest Expense was $0.00 Mil. Its Operating Income was $-5.07 Mil. And its Long-Term Debt & Capital Lease Obligation was $2.54 Mil.

GuruFocus does not calculate CollPlant Biotechnologies's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

CollPlant Biotechnologies (NAS:CLGN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

CollPlant Biotechnologies Interest Coverage Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies (CollPlant Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

CPT:Germany

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.